ArticleIndian journal of orthopaedics2026
Assessing the Potential of CD11c as a Biomarker for Identifying Ideal Donors in Hyaline Cartilage Repair.
Article in Indian journal of orthopaedics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: α10β1 integrin (CD11c/CD29) receptor plays a critical role in anchoring chondrocytes to the extracellular matrix and mediating essential collagen type II interactions being its primary receptor, thereby influencing cartilage integrity, matrix synthesis, and organization. Given the challenges with hyaline cartilage regeneration, particularly the tendency of chondrocytes to adopt a fibrocartilaginous phenotype due to donor variability and extensive passage, this study sought to discern differences in chondrogenic potential between high and low donor groups based on CD11c expression and assess its potential as a tool for selecting high-potential donors to streamline the evaluation process. Materials and methods: Enzymatically isolated chondrocytes from six donors underwent FACS analysis to determine CD11c expression levels, and based on the median levels, the chondrocytes were categorized into low and high expression groups, and their chondrogenic potential was compared using FACS for putative markers of chondrogenesis, gene expression patterns, differentiation studies and biochemical analysis of total glycosaminoglycan/DNA ratios and total Collagen type II levels. Result: High donor group displayed higher variability with CD29 and CD146 but comparability with the low donor group. Although the high donor group exhibited lower expression of hypertrophic markers (COL1A1 and RUNX2), suggesting potential phenotypic advantages, no significant differences were observed in chondrogenic potential or ECM properties between the two groups. Conclusion: The novel data demonstrate that moderate CD11c percentage expression with fresh chondrocytes is not a reliable marker for distinguishing donors with superior chondrogenic potential. Reanalysis using higher percentage expressions and exploring alternative combinations of markers would help identify optimal donors. Supplementary Information: The online version contains supplementary material available at 10.1007/s43465-025-01577-1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.